Advertisement

Russian Journal of General Chemistry

, Volume 89, Issue 7, pp 1388–1393 | Cite as

Synthesis and Biological Activity of N-Aryl(alkyl)-2-[2-(9H-fluoren-9-ylidene)hydrazinylidene]-5,5-dimethyl-4-oxohexanamides

  • A. I. SiutkinaEmail author
  • N. M. Igidov
  • M. V. Dmitriev
  • R. R. Makhmudov
  • V. V. Novikova
Article
  • 3 Downloads

Abstract

Ring opening of 5-tert-butyl-3-[(9H-fluoren-9-ylidene)hydrazinylidene]furan-2(3H)-one by the action of primary amines afforded a series of new 2-[(9H-fluoren-9-ylidene)hydrazinylidene]-5,5-dimethyl-4-oxohexan-amides. The synthesized compounds were tested for antinociceptive and antimicrobial activities.

Keywords

5-tert-butyl-3-[(9H-fluoren-9-ylidene)hydrazinylidene]furan-2(3H)-one N-aryl(alkyl)-2-[(9H-fluoren-9-ylidene)hydrazinylidene]-5,5-dimethyl-4-oxohexanamides antinociceptive activity antimicrobial activity antifungal activity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shipilovskikh, S.A., Rubtsov, A.E., Makhmudov, R.R., and Zalesov, V.V., RU Patent no. 2 389 724, 2008; Byull. Izobret., 2010, no. 14.Google Scholar
  2. 2.
    Shipilovskikh, S.A., Makhmudov, R.R., Lupach, D.Yu., Pavlov, P.T., Babushkina, E.V., and Rubtsov, A.E., Pharm. Chem. J., 2013, vol. 47, no. 7, p. 366. doi  https://doi.org/10.1007/s11094-013-0960-z CrossRefGoogle Scholar
  3. 3.
    Bykov, R.A., Trapeznikova, N.N., Balandina, S.Yu., Komarova, O.A., Makhmudov, R.R., Pulina, N.A., Sobin, F.V., and Rubtsov, A.E., Pharm. Chem. J., 2018, vol. 52, no. 5, p. 415. doi  https://doi.org/10.1007/s11094-018-1833-2 CrossRefGoogle Scholar
  4. 4.
    Pulina, N.A., Kozhukhar, V.Y., Kuznetsov, A.S., Starkova, A.V., and Rubtsov, A.E., Russ. Chem. Bull., Int. Ed., 2017, vol. 66, no. 8, p. 1497. doi  https://doi.org/10.1007/s11172-017-1914-5 CrossRefGoogle Scholar
  5. 5.
    Igidov, N.M., Makhmudov, R.R., and Fedorovtseva, A.N., RU Patent no. 2347072, 2007; Byull. Izobret., 2009, no. 3.Google Scholar
  6. 6.
    Komarova, O.A., Igidov, N.M., Rubtsov, A.E., Zalesov, V.V., Makarov, A.S., and Toksarova, Yu.S., Russ. J. Org. Chem., 2010, vol. 46, no. 2, p. 236. doi  https://doi.org/10.1134/S1070428010020156 CrossRefGoogle Scholar
  7. 7.
    Tyuneva, A.V., Igidov, N.M., Koryagina, N.N., Borodin, A. Yu., Zakhmatov, A.V., Makarov, A.S., Toksarova, Yu.S., and Rubtsov, A.E., Russ. J. Org. Chem., 2011, vol. 47, no. 2, p. 258. doi  https://doi.org/10.1134/S1070428011020163 CrossRefGoogle Scholar
  8. 8.
    Pulina, N.A., Kuznetsov, A.S., and Rubtsov, A.E., Russ. J. Org. Chem., 2015, vol. 51, no. 7, p. 967. doi  https://doi.org/10.1134/S1070428015070131 CrossRefGoogle Scholar
  9. 9.
    Shipilovskikh, S.A. and Rubtsov, A.E., Russ. J. Org. Chem., 2014, vol. 50, no. 2, p. 298. doi  https://doi.org/10.1134/S1070428014020286 CrossRefGoogle Scholar
  10. 10.
    Shipilovskikh, S.A. and Rubtsov, A.E., Russ. Chem. Bull., Int. Ed., 2014, vol. 63, no. 9, p. 2205. doi  https://doi.org/10.1007/s11172-014-0722-4 CrossRefGoogle Scholar
  11. 11.
    Kuznetsov, A.S., Pulina, N.A., and Rubtsov, A.E., Abstracts of Papers, Mezhdunarodnyi kongress Kost-2015 (Int. Congr. Kost-2015), Moscow, 2015, p. 456.Google Scholar
  12. 12.
    CrysAlisPro. Version 1.171.37.33 (release 27-03-2014 CrysAlis171.NET), Agilent Technologies.Google Scholar
  13. 13.
    Sheldrick, G.M., Acta Crystallogr., Sect. A, 2008, vol. 64, no. 1, p. 112. doi  https://doi.org/10.1107/S0108767307043930 CrossRefGoogle Scholar
  14. 14.
    Sheldrick, G.M., Acta Crystallogr., Sect. C., 2015, vol. 71, no. 1, p. 3. doi  https://doi.org/10.1107/S2053229614024218 CrossRefGoogle Scholar
  15. 15.
    Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, and Howard, J.A.K., and Puschmann, H.J., Appl. Crystallogr., 2009, vol. 42, p. 339. doi  https://doi.org/10.1107/S0021889808042726 CrossRefGoogle Scholar
  16. 16.
    Komarova, O.A., Igidov, N.M., Koryagina N.N., Makarov A.S., Toksarova, Yu.S., and Rubtsov, A.E., Russ. J. Org. Chem, 2011, vol. 47, no. 1, p. 109. doi  https://doi.org/10.1134/S1070428011010131 CrossRefGoogle Scholar
  17. 17.
    Eddy, N.B. and Leimbach, D.J., J. Pharmacol. Exp. Ther., 1953, vol. 107, no. 3, p. 385.Google Scholar
  18. 18.
    Mironov, A.N., Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh veshchestv, (A Guide to Preclinical Trials of Drugs), Moscow: Grif i K 2012, part 1, p. 509.Google Scholar
  19. 19.
    Belen’kii, M.L., Elementy kolichestvennoi otsenki farmakologicheskogo effekta, (Elements of Quantitative Estimation of Pharmacological Effect), Leningrad: Medgiz 1963.Google Scholar
  20. 20.
    Novikova, VV. and Russkikh, A.A., Razrab. Regist. Lek. Sredstv, 2018, no. 2 (23), p. 32.Google Scholar

Copyright information

© Pleiades Publishing, Ltd. 2019

Authors and Affiliations

  • A. I. Siutkina
    • 1
    Email author
  • N. M. Igidov
    • 1
  • M. V. Dmitriev
    • 2
  • R. R. Makhmudov
    • 2
    • 3
  • V. V. Novikova
    • 1
  1. 1.Ministry of Health Protection of the Russian FederationPerm State Pharmaceutical AcademyPermRussia
  2. 2.Perm State National Research UniversityPermRussia
  3. 3.Federal Research Center for Medical and Preventive Health Risk Management TechnologiesPermRussia

Personalised recommendations